ECSP24001599A - PHARMACEUTICAL COMPOSITION OF NON-ENCAPSULATED VIRUS - Google Patents

PHARMACEUTICAL COMPOSITION OF NON-ENCAPSULATED VIRUS

Info

Publication number
ECSP24001599A
ECSP24001599A ECSENADI20241599A ECDI202401599A ECSP24001599A EC SP24001599 A ECSP24001599 A EC SP24001599A EC SENADI20241599 A ECSENADI20241599 A EC SENADI20241599A EC DI202401599 A ECDI202401599 A EC DI202401599A EC SP24001599 A ECSP24001599 A EC SP24001599A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
encapsulated virus
compositions
virus
encapsulated
Prior art date
Application number
ECSENADI20241599A
Other languages
Spanish (es)
Inventor
Dmitry Valentinovich Morozov
Ekaterina Aleksandrovna Lomkova
Aleksandr Olegovich Iakovlev
Marina Konstantinovna Dvoriankina
Aleksandra Aleksandrovna Sozonova
Lina Igorevna Fedorenko
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2860958C2/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of ECSP24001599A publication Critical patent/ECSP24001599A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con el campo de la farmacéutica, terapia genética y medicina, específicamente con las composiciones farmacéuticas de un vector de un virus no encapsulado recombinante, en particular, el virus adeno-asociado recombinante (rAAV), cuyas composiciones pueden ser composiciones acuosas o liofilizadas y pueden utilizarse para el tratamiento y la prevención de varias enfermedades.The present invention relates to the field of pharmaceuticals, gene therapy and medicine, specifically with the pharmaceutical compositions of a vector of a recombinant non-encapsulated virus, in particular, the recombinant adeno-associated virus (rAAV), whose compositions can be compositions aqueous or lyophilized and can be used for the treatment and prevention of various diseases.

ECSENADI20241599A 2021-07-08 2024-01-08 PHARMACEUTICAL COMPOSITION OF NON-ENCAPSULATED VIRUS ECSP24001599A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021120143A RU2860958C2 (en) 2021-07-08 Pharmaceutical composition of non-enveloped virus

Publications (1)

Publication Number Publication Date
ECSP24001599A true ECSP24001599A (en) 2024-02-29

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20241599A ECSP24001599A (en) 2021-07-08 2024-01-08 PHARMACEUTICAL COMPOSITION OF NON-ENCAPSULATED VIRUS

Country Status (12)

Country Link
EP (1) EP4367252A4 (en)
CN (1) CN117999353A (en)
AR (1) AR126417A1 (en)
CL (1) CL2024000062A1 (en)
CO (1) CO2024000073A2 (en)
CR (1) CR20240004A (en)
EC (1) ECSP24001599A (en)
JO (1) JOP20240003A1 (en)
MA (1) MA63861A1 (en)
MX (1) MX2024000472A (en)
WO (1) WO2023282796A2 (en)
ZA (1) ZA202400124B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503893A (en) * 2023-01-19 2026-02-02 ユニキュアー バイオファーマ ビー．ブイ． Pharmaceutical Formulations of Gene Delivery Vehicles
TW202525313A (en) * 2023-09-06 2025-07-01 瑞士商迪納柯公司 Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations
WO2025114524A1 (en) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025263459A1 (en) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 Biopharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
JP6013654B2 (en) * 2013-09-19 2016-10-25 クルセル ホランド ベー ヴェー Improved adenovirus formulation
BR112019009113A2 (en) * 2016-11-04 2019-07-16 Baxalta Incorporated adeno-associated virus formulations
CN112770812A (en) * 2018-07-24 2021-05-07 沃雅戈治疗公司 System and method for producing gene therapy formulations

Also Published As

Publication number Publication date
MA63861A1 (en) 2024-10-31
CR20240004A (en) 2024-06-11
ZA202400124B (en) 2024-11-27
EP4367252A4 (en) 2025-04-30
WO2023282796A2 (en) 2023-01-12
EP4367252A2 (en) 2024-05-15
JOP20240003A1 (en) 2024-01-08
MX2024000472A (en) 2024-02-12
AR126417A1 (en) 2023-10-11
CL2024000062A1 (en) 2024-06-14
CN117999353A (en) 2024-05-07
CO2024000073A2 (en) 2024-04-29
WO2023282796A3 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
ECSP24001599A (en) PHARMACEUTICAL COMPOSITION OF NON-ENCAPSULATED VIRUS
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112021015751A2 (en) Gene therapy vectors for the treatment of danon's disease
BR112014019431A8 (en) COMPARTMENTALIZED METHOD OF DELIVERY OF NUCLEIC ACID AND COMPOSITIONS AND USES THEREOF
MX2023010365A (en) Room temperature stable lyophilized protein.
MX2023010328A (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof.
EA202091308A1 (en) MODIFIED BRUCELLA VACCINE STRAIN FOR THE TREATMENT OF BRUCELLOSIS
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
AR116569A1 (en) GENE THERAPY TO TREAT PROPIONIC ACIDEMIA
MX2023009921A (en) Formulations of ace2 fc fusion proteins.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR112015023806A2 (en) NEW CELGOSIVIR DOSING REGIMES FOR THE TREATMENT OF DENGUE
EA202090666A1 (en) APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY
PH12022550238A1 (en) Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
EP4480492A3 (en) Novel insulin analogues and uses thereof
CO2023004031A2 (en) Systemic administration of adeno-associated virus vector expressing sarcoglycan g and treatment of muscular dystrophy
BR112019024796A2 (en) PEPTIDES AND USES OF THE SAME AS ANTI-VIRAL AGENTS
MX2024009890A (en) THERAPEUTIC FACTORS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
BR112022009834A2 (en) CTGF-SPECIFIC DOUBLE-STRAND OLIGONUCLEOTIDE, CONSTRUCT, NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS TO PREVENT OR TREAT FIBROSIS AND RESPIRATORY DISEASES AND LYOPHILIZED FORMULATIONS
BR112017022390A2 (en) The medical treatment and/or the medicine constituent for prevention of cancer
ZA202401042B (en) Protein compositions for the treatment of inflammatory diseases
JOP20220313A1 (en) levelimab aqueous formulation and its uses
MX2019014697A (en) Rage proteins for the treatment of fibrosis and dna damage mediated diseases.
GEAP202516788A (en) Pharmaceutical composition of non-enveloped virus
BR112022011976A2 (en) COMPOSITION TO TREAT OR PREVENT AN ALLERGY OR ALLERGIC REACTION